Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Daito Pharmaceutical Co's PB Ratio or its related term are showing as below:
TSE:4577'
s PB Ratio Range Over the Past 10 Years
Min: 0.56 Med: 1.09 Max: 1.91
Current: 0.71
During the past 13 years, Daito Pharmaceutical Co's highest PB Ratio was 1.91. The lowest was 0.56. And the median was 1.09.
TSE:4577's PB Ratio is ranked better than 85.39% of 924
companies
in the Drug Manufacturers industry
Industry Median: 1.895
vs TSE:4577: 0.71
During the past 12 months, Daito Pharmaceutical Co's average Book Value Per Share Growth Rate was 6.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 4.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 5.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 8.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Daito Pharmaceutical Co was 19.70% per year. The lowest was 4.80% per year. And the median was 10.60% per year.
Back to Basics: PB Ratio
Daito Pharmaceutical Co (TSE:4577) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Daito Pharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daito Pharmaceutical Co PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daito Pharmaceutical Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Daito Pharmaceutical Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Daito Pharmaceutical Co (TSE:4577) has a PB Ratio of 0.71 as of Jul. 20, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Daito Pharmaceutical Co and its competitors. This is 35% below median its historical median of 1.09. Over the past decade, Daito Pharmaceutical Co's PB Ratio has ranged from 0.56 to 1.91. According to the industry distribution chart, Daito Pharmaceutical Co ranks #135 out of 924 companies in the Drug Manufacturers industry, placing it in the top 14.6%.
Is Daito Pharmaceutical Co's PB Ratio too high?
Daito Pharmaceutical Co's current PB Ratio of 0.71 is 35% below median its 10-year median of 1.09. Over the past 10 years, this metric has ranged from a low of 0.56 to a high of 1.91. The Drug Manufacturers industry median PB Ratio is 1.90. Daito Pharmaceutical Co's value of 0.71 is 62.5% below this industry median. Based on the distribution chart, Daito Pharmaceutical Co ranks #135 out of 924 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Daito Pharmaceutical Co has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Daito Pharmaceutical Co's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Daito Pharmaceutical Co ranks #135 out of 924 companies for PB Ratio. This places Daito Pharmaceutical Co in the top 15% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.90. Daito Pharmaceutical Co's value of 0.71 is 62.5% below this benchmark. Historically, Daito Pharmaceutical Co's own PB Ratio has ranged from 0.56 to 1.91 over the past decade. While the company's 10-year median is 1.09 vs. the industry median of 1.90, Daito Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 924 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daito Pharmaceutical Co's current PB Ratio of 0.71 is 62.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Daito Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daito Pharmaceutical Co's current PB Ratio is 0.71, which is 35% below median its own 10-year median of 1.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daito Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Daito Pharmaceutical Co (TSE:4577) is currently considered Fairly Valued. The stock's GF Value™ is 円1,278.52, compared to a current price of 円1,309.00 — trading 2.4% above its estimated fair value. The current PB Ratio is 0.71, which is 35% below median its 10-year median of 1.09 and 62.5% below the Drug Manufacturers industry median of 1.90. Daito Pharmaceutical Co's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Daito Pharmaceutical Co (TSE:4577), the current PB Ratio is 0.71 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daito Pharmaceutical Co (TSE:4577) Overvalued in 2026?
Based on GuruFocus' analysis, Daito Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円1,309.00 is trading 2.4% above its estimated GF Value™ of 円1,278.52.
GuruFocus considers Daito Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4577:
PB Ratio: 0.71 (35% below median its 10-year median of 1.09)
GF Value™: 円1,278.52 vs. price of 円1,309.00 (2.4% above fair value)
Industry Position: 62.5% below the Drug Manufacturers median (#135 of 924)
No single metric tells the full story. See the TSE:4577 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4577 has been successfully added to your 
